Proposed article structure
This topic is best organized around the clinical problem of biochemical persistence after surgery for medullary thyroid carcinoma, the rationale for dynamic biomarker kinetics, the retrospective cohort design, the main prognostic findings, and the implications for surveillance and risk-adapted follow-up. A clinically useful structure is: Highlights; Background and unmet need; Study design and methods; Key results; Clinical interpretation and expert commentary; Practice implications; Limitations; Conclusion; Funding and trial registration; References.
Highlights
Among patients with medullary thyroid carcinoma and biochemical persistent disease after surgery, an early postoperative calcitonin doubling rate of at least 0.3/year identified a markedly higher risk of structural recurrence.
At 10 years, relapse-free survival was 45.3% in patients with calcitonin doubling rate at least 0.3/year versus 89.2% in those below this threshold.
On multivariable analysis, calcitonin doubling rate at least 0.3/year remained an independent predictor of recurrence, alongside tumor size greater than 4 cm and pathologic extrathyroidal extension.
Calcitonin doubling rate appeared to provide information that was not captured by most classic clinicopathologic features, supporting its role as a dynamic postoperative risk marker.
Background and unmet clinical need
Medullary thyroid carcinoma is a neuroendocrine malignancy arising from parafollicular C cells of the thyroid. Compared with differentiated thyroid cancers, medullary thyroid carcinoma has a distinct biology, does not respond to radioactive iodine, and relies heavily on surgery for curative treatment. Serum calcitonin is a central biomarker in this disease because it reflects tumor burden and often detects persistent or recurrent disease earlier than imaging.
A difficult postoperative subgroup is the patient with biochemical persistent disease: serum calcitonin remains detectable or elevated after initial surgery, but no structurally evident recurrence may yet be found. These patients are known to be at increased risk of later relapse, but their outcomes are heterogeneous. Some remain stable for years with low-volume indolent disease, while others progress to clinically meaningful locoregional or distant recurrence.
This heterogeneity creates a practical problem. If all such patients are followed with the same intensity, some may undergo excessive imaging and anxiety-provoking surveillance, while others at genuinely high risk may not be monitored closely enough. Static clinicopathologic factors such as tumor size, nodal disease, and extrathyroidal extension are useful, but they do not fully capture residual tumor behavior after surgery. Dynamic biomarker kinetics may therefore offer a more individualized estimate of biological aggressiveness.
Calcitonin doubling time has long been recognized as prognostically important in medullary thyroid carcinoma, and current guideline discussions often refer to short doubling times as markers of poor prognosis. The present study by Yamamoto and colleagues examines a related but distinct parameter, calcitonin doubling rate, measured within 2 years after surgery, specifically in patients with biochemical persistent disease. The question is clinically relevant: can early postoperative calcitonin kinetics identify which biochemically persistent patients are most likely to recur?
Study design and methods
This was a retrospective single-center cohort study conducted at Kuma Hospital, including 265 patients who underwent surgery for medullary thyroid carcinoma between 1997 and 2022. An important methodological strength is that all patients underwent germline RET mutation analysis, which is relevant given the hereditary forms of medullary thyroid carcinoma and the established prognostic and therapeutic implications of RET alterations.
From the full cohort, the investigators identified 65 patients with biochemical persistent disease who had enough postoperative calcitonin measurements to allow calculation of calcitonin doubling rate within 2 years after surgery. This analytic restriction is sensible for the primary question, although it also narrows the sample and may introduce selection effects related to follow-up completeness.
The main outcome was relapse-free survival. Recurrence risk was assessed using Kaplan-Meier methods and Cox proportional hazards models. Receiver operating characteristic analysis was used to identify an optimal cutoff for calcitonin doubling rate in predicting recurrence, yielding a threshold of 0.3/year. The study also evaluated the relationship between calcitonin doubling rate and standard clinicopathologic variables.
The use of a doubling rate rather than a doubling time deserves brief clarification. Doubling time becomes difficult to interpret when biomarker trajectories are flat or declining, whereas a rate-based formulation can be statistically and clinically more tractable across a broader range of patterns. In practice, both aim to describe the tempo of biomarker change, but the rate metric may be easier to incorporate into risk models when early postoperative values are variable.
Key findings
Recurrence was common enough to justify risk refinement
During follow-up, 15 of 65 patients with biochemical persistent disease, or 23.1%, developed recurrence. This confirms that biochemical persistence after surgery is not a trivial finding. At the same time, most patients did not recur during the observation period, underscoring why finer risk stratification is needed.
Calcitonin doubling rate at least 0.3/year identified a distinctly higher-risk group
The central finding is the prognostic separation achieved by the calcitonin doubling rate threshold derived from receiver operating characteristic analysis. Patients with a calcitonin doubling rate of at least 0.3/year had significantly worse relapse-free survival than those with a rate below 0.3/year, with a log-rank P value below .01.
The magnitude of the survival difference is clinically impressive. Ten-year relapse-free survival was 45.3% in the higher-rate group compared with 89.2% in the lower-rate group. For a biomarker-based stratifier measured within 2 years of surgery, that degree of separation suggests substantial clinical utility.
The prognostic effect persisted after adjustment for tumor factors
In multivariable analysis, calcitonin doubling rate at least 0.3/year remained independently associated with recurrence, with a hazard ratio of 8.24 and a 95% confidence interval of 2.31 to 29.48. Although the confidence interval is wide, as expected in a modest-sized cohort with 15 events, the lower bound remains meaningfully above 1, supporting a robust signal.
Two additional independent predictors emerged: tumor size greater than 4 cm and pathologic extrathyroidal extension. This is biologically plausible. Larger primary tumors and invasive local growth are established markers of more advanced disease and may reflect greater residual microscopic burden or intrinsically more aggressive tumor biology.
Calcitonin doubling rate added information beyond most classic prognostic variables
A notable observation is that calcitonin doubling rate showed no significant association with most classic clinicopathologic risk factors. In other words, the biomarker kinetics were not merely a surrogate for the usual pathologic features. Instead, they appear to capture a separate dimension of risk: the actual postoperative growth behavior of residual disease.
The study did find an inverse association between calcitonin doubling rate and age, suggesting younger patients had faster biomarker rise. That finding is interesting but should be interpreted cautiously. It could reflect differences in tumor biology, hereditary disease patterns, surveillance intensity, or residual confounding. Still, it raises the possibility that dynamic biomarker behavior may vary across age groups in ways not fully explained by stage or pathology.
Clinical interpretation and expert commentary
The practical message is straightforward: among patients with medullary thyroid carcinoma who have persistent postoperative calcitonin elevation, not all carry the same recurrence risk, and early biomarker kinetics can help separate indolent from higher-risk courses. This matters because biochemical persistence is common enough to challenge clinicians, yet structural recurrence may take years to become evident.
Current management of medullary thyroid carcinoma already relies heavily on serial calcitonin and carcinoembryonic antigen measurements, together with imaging tailored to biochemical burden and kinetics. The American Thyroid Association guidelines for medullary thyroid carcinoma have long recognized calcitonin and carcinoembryonic antigen doubling times as clinically relevant prognostic tools. What this study contributes is a focused analysis of a particularly important postoperative subgroup and a concrete rate threshold, 0.3/year, that may be useful in follow-up planning.
From a translational standpoint, the result is biologically plausible. Residual medullary thyroid carcinoma that continues to secrete calcitonin at an accelerating pace is likely to represent active tumor growth rather than a stable residual cell population. Dynamic change in a tumor-specific biomarker can therefore outperform static postoperative status alone. A patient with low-level persistent calcitonin after surgery may not warrant the same concern if values are flat or slowly changing, whereas a patient with a clear upward kinetic pattern likely merits closer imaging surveillance and more frequent biochemical reassessment.
At the same time, clinicians should avoid overinterpreting the exact threshold as universally definitive. Cutoffs derived from receiver operating characteristic analyses are often cohort-specific and may shift across institutions depending on assay methods, sampling intervals, surgical case mix, and recurrence definitions. The signal is convincing, but external validation will be essential before the 0.3/year threshold is adopted as a formal standard.
Implications for practice
For endocrine surgeons, endocrinologists, and oncologists, this study supports a more risk-adapted surveillance framework after surgery for medullary thyroid carcinoma.
First, patients with biochemical persistent disease should not be considered a uniform category. Early postoperative calcitonin kinetics can identify those who may need intensified follow-up.
Second, a calcitonin doubling rate at least 0.3/year, especially when combined with tumor size greater than 4 cm or pathologic extrathyroidal extension, may justify closer biochemical testing and lower thresholds for structural imaging of the neck and distant sites when clinically appropriate.
Third, patients with persistent but kinetically indolent calcitonin values may be suitable for less aggressive surveillance intervals, although this should be individualized and balanced against hereditary risk, absolute biomarker levels, imaging findings, and symptoms.
Fourth, these findings may also become relevant in the era of selective RET inhibitors. Although this study addresses recurrence risk rather than systemic treatment selection, more refined postoperative risk stratification could help determine which patients need earlier referral to multidisciplinary teams, molecular review, or closer assessment for future therapeutic intervention.
Limitations
Several limitations should temper interpretation. The study was retrospective and conducted at a single high-volume center. Such centers often have consistent surgical expertise and follow-up protocols, which is a strength for internal validity but may limit generalizability to broader practice settings.
The sample size of the key analytic cohort was modest, with only 65 patients and 15 recurrences. This constrains statistical power and likely explains the wide confidence intervals around the hazard ratio estimates. Multivariable findings are compelling but should still be considered hypothesis-strengthening rather than definitive.
The analysis included only patients with sufficient calcitonin measurements within 2 years of surgery. Patients lacking adequate data were excluded, which may introduce selection bias if measurement frequency was influenced by physician concern, patient adherence, or underlying disease characteristics.
The abstract does not provide granular details on imaging protocols, the exact definition of recurrence, assay standardization over the long study period, or the distribution of hereditary versus sporadic disease. Given the study period spanning 1997 to 2022, changes in imaging sensitivity, laboratory platforms, and treatment practices could have influenced ascertainment and follow-up.
Finally, carcinoembryonic antigen kinetics were not highlighted in the abstracted results. Because carcinoembryonic antigen is another established biomarker in medullary thyroid carcinoma, it would be valuable to know whether combined kinetic models improve prognostic performance beyond calcitonin alone.
Conclusion
This study provides clinically useful evidence that early postoperative calcitonin doubling rate can refine recurrence risk assessment in medullary thyroid carcinoma patients with biochemical persistent disease. A calcitonin doubling rate of at least 0.3/year identified a subgroup with substantially worse long-term relapse-free survival, independent of major pathologic risk factors. The findings support a shift from static classification toward dynamic postoperative risk assessment.
For clinicians, the take-home message is not simply that persistent calcitonin matters, but that the direction and speed of change matter greatly. If externally validated, calcitonin doubling rate could become a practical tool for tailoring surveillance intensity, counseling patients more accurately, and prioritizing resources toward those most likely to develop structural recurrence.
The next steps are clear: multicenter validation, integration with absolute biomarker levels and carcinoembryonic antigen kinetics, and prospective evaluation of whether rate-guided surveillance improves outcomes or efficiency. Until then, this study adds meaningful evidence in favor of using postoperative biomarker dynamics as part of individualized care in medullary thyroid carcinoma.
Funding and trial registration
The abstract does not report a funding source or a ClinicalTrials.gov registration number. This is consistent with a retrospective observational study design, which may not require trial registration.
References
Yamamoto M, Miyauchi A, Kihara M, Fujishima M, Sasaki T, Kawano S, Ito Y, Miya A. Postoperative risk stratification using calcitonin doubling rate in medullary thyroid carcinoma with biochemical persistent disease. Surgery. 2026-04-18;195:110208. PMID: 42001646.
Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610. PMID: 25810047.
Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF; GTE Study Group. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90(11):6077-6084. PMID: 16091497.
Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A, Pacini F. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004;89(1):163-168. PMID: 14715840.
